{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-119757","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.374288+00:00","generated_at":"2026-05-15T09:23:39.881271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026","bullets":["Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.","Full year net loss $242.0M ($32.37 per share) vs $63.6M in 2024, driven by non-cash PIPE-related charges (tranche liability, warrant revaluation).","No collaboration revenue in 2025 vs $10M in 2024; research service revenue from terminated TCGFB deal was $3.5M.","Received $5M milestone from Boehringer Ingelheim for SZN-413 after successful IND-enabling GLP tox study.","On track to submit IND for SZN-8141 (retinal disease) to FDA in H2 2026; will present at ARVO in May 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-119757","json":"https://secwatch.observer/filing/0001193125-26-119757.json","markdown":"https://secwatch.observer/filing/0001193125-26-119757.md","text":"https://secwatch.observer/filing/0001193125-26-119757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526119757/0001193125-26-119757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526119757/srzn-20260323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:23:39.881271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}